VRC-FLUDNA061-00-VP (Leidos Biomedical Research)

VRC-FLUDNA061-00-VP is an investigational trivalent DNA vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) for the prevention of seasonal influenza. The vaccine consists of three closed-circular plasmid DNA macromolecules (VRC-9328, VRC-2439, and VRC-9323) in equal amounts by weight. These plasmids encode the hemagglutinin (HA) sequences for three influenza strains matching the 2011/12 licensed inactivated influenza vaccine: A/California/04/2009 (H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. Expression of the HA antigens is driven by a CMV/R promoter. As a DNA vaccine, it works by delivering plasmid DNA into human cells, which then produce the influenza proteins to act as antigens and stimulate an immune response. It has been evaluated in Phase 1b clinical trials (VRC 701) as a prime vaccination followed by a trivalent inactivated vaccine (TIV) boost to enhance the breadth and durability of the immune response in healthy adults.

Other names

2011/12 Influenza Investigational DNA VaccineVRC 701 DNA vaccineVRC701 DNA vaccineVRC-701 DNA vaccinetrivalent seasonal influenza DNA vaccine